A study by the researchers from the United Kingdom and Sweden shows a reduction in the secretion of insulin with the blockage of vitamin 'A' receptors on the surface of beta cells, called as GPRC5C. They say new diabetes treatments can be developed using this discovery by targeting GPRC5C in the pancreas.
Researchers conducted experiments with mice models to know how beta cell receptors interact with vitamin 'A', after finding the vitamin 'A' receptors on the surface of the beta cells. Researchers found a reduction in the ability of the beta cells in the secretion of insulin in response to sugar or glucose levels with a partial blockage of vitamin 'A' receptors in the pancreas of the mice models. They also found 30 percent reduction to insulin secreting ability while conducting experiments with beta cells of humans (with and without type 2 diabetes T2D) by partially blocking GPRC5C (in beta cells) and applying sugar on them. With these experiments, they believe that lack of vitamin 'A' which causes a reduction in insulin secretion plays a role in the development of type 2 diabetes (T2D). Their study findings also suggest the role of vitamin 'A' in the development of type 1 diabetes (T1D), which is caused due to the destruction of beta cells in the pancreas.
They say children should absorb sufficient quantity of vitamin 'A' through their diet to prevent the development of diabetes as their experiments show newborn mice models needed vitamin 'A' for the normal growth of beta cells. But they say not to increase intake of vitamin 'A' through supplements as excess vitamin 'A' levels are associated with health problems such as osteoporosis.
Now the researchers are finding ways to activate GPRC5C on the surface of the beta cells to improve the functionality of beta cells which secrete insulin without causing side effects linked with vitamin 'A'. Co-author of the study was Albert Salehi, the University of Lund, Sweden. The study findings were published in The Japan Endocrine Society. Title of the article was "Anti-diabetic action of all-trans retinoic acid and the orphan G protein-coupled receptor GPRC5C in pancreatic β-cells".
Cabbages, broccoli and brussels sprouts contain a sulforaphane (SFN) compound and this was being used to treat cancer and chronic obstructive pulmonary disease (COPD). SFN also protects complications such as renal failure, neuropathy and atherosclerosis. In a first study done by the researchers shows regulation of blood sugar or glucose levels (HbA1c) of type 2 diabetes (T2D) patients with concentrated broccoli sprout extract which contains sulforaphane (SFN) compound.
Researchers initially conducted experiments with sulforaphane (SFN) compound on mice and rat models and their studies shows a reduction in glucose production by the liver cells and T2D gene expression. To know how a human body metabolized glucose with sulforaphane (SFN) compound, they conducted experiments among 103 obese individuals with hard-to-manage type 2 diabetes (T2D) condition. The study participants were on either placebo or broccoli sprout extract (BSE) dose (which contains sulforaphane SFN) for 12 weeks duration. Researchers observed blood sugar levels, side effects and other symptoms with the usage of broccoli sprout extract (BSE) dose.
The study findings show a significant reduction in blood sugar or glucose levels (HbA1c) without serious side effects with broccoli sprout extract (BSE) dose. But the authors say not to recommend broccoli sprout extract (BSE) dose as a drug treatment to type 2 diabetes (T2D) patients as the BSE needs further studies. 75 percent of the participants were male, aged between 35 to 75 years. The participants consumed refined broccoli sprout extract (BSE) dose. The study findings were published in the journal Science Translational Medicine. Title of the article was "Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes".
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.